Last mentioned: Mar 8, 2026
Earnings Previews
Seeking Alpha releases Q4 2025 previews for both Voyager and Zevra.
CFO Appointment
Zevra Therapeutics names Justin Renz as Chief Financial Officer.
Q4 2025 Earnings
Both companies report full-year 2025 results and 2026 guidance.
Olpruva Scaling
Zevra reports steady growth in urea cycle disorder market share.
Voyager Partnership Update
Voyager reports progress on TRACER platform milestones with Novartis.
Novartis Expansion
Voyager expands its capsid discovery collaboration with Novartis.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC treatment.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC.
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution and platform validation. Investors are focused on Zevra's Miplyffa launch trajectory and Voyager's CNS-focused partnership revenue.
Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 earnings, highlighting a critical juncture for gene therapy delivery and rare disease commercialization. Investors are prioritizing updates on the TRACER platform milestones and the market penetration of newly launched orphan drugs.